TARS News and Press, Tarsus Pharmaceuticals Inc. From 05/08/24

2024-05-08 17:08:37 ET More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript Tarsus Pharmaceuticals Q1 2024 Earnings Preview Tarsus refinances ex...

Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of ...

IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1...

2024-04-23 08:51:32 ET More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript Tarsus Pharmaceuticals stock dips after pricing $100M securities offering ...

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.97% on the day to $36.52. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic ...

2024-04-05 02:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-26 01:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-07 20:03:34 ET Summary TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M f...

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the...